Voluntary nationwide recall: Brexafemme

Oct. 2023Pharmacy Updates

Scynexis, Inc. is recalling two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets. This drug is used as an antifungal for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC). Read the full text of the voluntary Brexafemme recall.

Recent Announcements

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.

Nov. 2025Pharmacy Updates

Medicaid provider update: High-cost Medicaid drug billing

Billing requirements for Medicaid-covered drugs

Nov. 2025Important Notices

Training Webinar: Conversio Health COPD Management Program

Please join us for a live training webinar for primary care providers and pulmonologists by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.

Nov. 2025Education/Webinars